Please login to the form below
roxadustat
This page shows the latest roxadustat news and features for those working in and with pharma, biotech and healthcare.
FDA requests further safety trials for AZ, FibroGen’s roxadustat
Roxadustat is an oral medicine that could be the first in this new class of treatments. ... Roxadustat is approved in a number of countries, including China under the brand name Evrenzo.
Latest news
-
FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
Briefing documents published earlier this week raised questions over the safety profile of roxadustat. ... The committee members concluded that AZ and FibroGen should produce additional safety data for roxadustat in this indication prior to marketing of
-
FDA questions safety profile of AZ, FibroGen’s anaemia drug roxadustat
AZ and FibroGen are aiming for approval of roxadustat in anaemia caused by chronic kidney disease. ... Roxadustat is already approved in China – where CKD is a particularly pressing medical problems – under the brand name Evrenzo.
-
CHMP recommends eight new medicines for EU approval
Finally, the CHMP has adopted positive opinions for Astellas and FibroGen’s Evrenzo (Roxadustat) for the treatment of anaemia symptoms in chronic kidney disease patients.
-
Astellas files new application for expanded use of roxadustat in Japan
Astellas has set its sights on extending the use of roxadustat into Japan, for the treatment of anaemia associated with chronic kidney disease (CKD) in non-dialysis patients. ... Together with partner FibroGen, Astellas has submitted a supplemental New
-
GSK files anaemia drug daprodustat in Japan, its first market
Another oral HIF-PHI drug – AstraZeneca and FibroGen’s roxadustat– has already been approved in China for CKD anaemia.Additional competition could come from Akebia, which has a drug in the ... Astellas Pharma meanwhile has rights to roxadustat in
More from news
Approximately 5 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD).
-
China: AstraZeneca’s new engine for growth and innovation
Roxadustat is under accelerated review and, if approved, would also be the first locally- developed medicine to hit the Chinese market even before Europe and the US,” says Mallon. ... Finally, a data readout for roxadustat is expected by the end of 2018
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
I am energised to join a company with such an innovative pipeline, as well as the first-in-class asset roxadustat, which has the potential to change the treatment paradigm in
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Sanofi Global Health unveils new nonprofit Impact brand
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- My journey advancing the science in pulmonary hypertension
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- The Power of AI in Medical Education
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- A creative awakening – how pharma is bringing innovation to the patient journey
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Shionogi Europe and NHS England agree on antibiotic subscription model
PMHub
90TEN
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
